# Methylated 1,2-naphthoquinone derivative SJ006 as an inhibitor of human glucose 6-phosphate dehydrogenase in non-small cell lung cancer cell lines

**Authors:** Makamas Chanda, Warinthorn Chavasiri, Panupong Mahalapbutr, Thanyada Rungrotmongkol, Poonlarp Cheepsunthorn, Chalisa Louicharoen Cheepsunthorn

PMC · DOI: 10.1038/s41598-025-20702-6 · Scientific Reports · 2025-10-21

## TL;DR

This study identifies SJ006, a natural compound, as a new inhibitor of G6PD in lung cancer cells, showing potential as an anticancer treatment.

## Contribution

SJ006 is a novel uncompetitive G6PD inhibitor that disrupts redox balance and cell proliferation in NSCLC.

## Key findings

- SJ006 inhibits G6PD activity without affecting its mRNA or protein levels.
- SJ006 induces ROS, G2/M arrest, and apoptosis in NSCLC cells.
- Molecular docking confirms strong G6PD binding by SJ006.

## Abstract

Glucose 6-phosphate dehydrogenase (G6PD) is crucial for redox balance and biosynthesis via the pentose phosphate pathway (PPP), driving non-small cell lung cancer (NSCLC) proliferation. This study assessed the cytotoxic and enzymatic effects of five 1,2-naphthoquinone (NQ) derivatives, including SJ006 derived from Usnea barbata, in NSCLC cell lines (A549 and NCI-H292) compared to traditional inhibitors (DHEA and 6AN). All 1,2-NQs demonstrated concentration-dependent cytotoxicity against NSCLC cells. Among them, NN02 exhibited the highest cytotoxicity comparable to 6-AN, followed by NN01, NN04, SJ006, and SJ007, which showed moderate effects comparable to DHEA. SJ006 uniquely inhibited G6PD activity without altering its mRNA or protein expression. Unlike DHEA and 6AN, SJ006 functioned as an uncompetitive inhibitor, decreasing both Km and Vmax, with molecular docking confirming strong G6PD binding. Additionally, SJ006 increased reactive oxygen species (ROS) levels, induced G2/M cell cycle arrest, and triggered late apoptosis in NSCLC cells. Its effects were reversed by D-(−)-ribose, confirming PPP disruption as the mechanism. These results highlight SJ006 as a novel G6PD inhibitor that disrupts redox homeostasis and biosynthesis-driven cell proliferation, showing promise as an anticancer agent for NSCLC.

The online version contains supplementary material available at 10.1038/s41598-025-20702-6.

## Linked entities

- **Genes:** G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539]
- **Proteins:** G6PD (glucose-6-phosphate dehydrogenase)
- **Chemicals:** 1,2-naphthoquinone (PubChem CID 10667), DHEA (PubChem CID 5881), 6AN (PubChem CID 9500), D-(−)-ribose (PubChem CID 854)
- **Diseases:** non-small cell lung cancer (MONDO:0005233), NSCLC (MONDO:0005233)

## Full-text entities

- **Genes:** G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}
- **Diseases:** NSCLC (MESH:D002289), cytotoxic (MESH:D064420)
- **Chemicals:** DHEA (MESH:D003687), pentose phosphate (MESH:D010428), ROS (MESH:D017382), D-(-)-ribose (MESH:D012266), 1,2-naphthoquinone (MESH:C040756), 6-AN (MESH:C050850), Methylated (-)
- **Species:** Usnea barbata (species) [taxon 192174], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** NCI-H292 — Homo sapiens (Human), Lung mucoepidermoid carcinoma, Cancer cell line (CVCL_0455), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12540661/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12540661/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12540661/full.md

---
Source: https://tomesphere.com/paper/PMC12540661